Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma
Abstract
Background: Malignant gliomas are deadly tumours with few therapeutic options. Although immunotherapy may be a promising therapeutic strategy for treating gliomas, a significant barrier is the CD11b+ tumour-associated myeloid cells (TAMCs), a heterogeneous glioma infiltrate comprising up to 40% of a glioma's cellular mass that inhibits anti-tumour T-cell function and promotes tumour progression. A theranostic approach uses a single molecule for targeted radiopharmaceutical therapy (TRT) and diagnostic imaging; however, there are few reports of theranostics targeting the tumour microenvironment. Methods: Utilizing a newly developed bifunctional chelator, Lumi804, an anti-CD11b antibody (αCD11b) was readily labelled with either Zr-89 or Lu-177, yielding functional radiolabelled conjugates for PET, SPECT, and TRT. Findings: 89Zr/177Lu-labeled Lumi804-αCD11b enabled non-invasive imaging of TAMCs in murine gliomas. Additionally, 177Lu-Lumi804-αCD11b treatment reduced TAMC populations in the spleen and tumour and improved the efficacy of checkpoint immunotherapy. Interpretation: 89Zr- and 177Lu-labeled Lumi804-αCD11b may be a promising theranostic pair for monitoring and reducing TAMCs in gliomas to improve immunotherapy responses.
- Authors:
-
more »
- Univ. of Pittsburgh, PA (United States)
- Lumiphore, Inc., Berkeley, CA (United States)
- Univ. of Missouri, Columbia, MO (United States)
- Univ. of Pittsburgh, PA (United States); Univ. of Missouri, Columbia, MO (United States)
- Publication Date:
- Research Org.:
- Univ. of Pittsburgh, PA (United States)
- Sponsoring Org.:
- USDOE Office of Science (SC), Nuclear Physics (NP); UPMC Hillman Cancer Center
- OSTI Identifier:
- 1904053
- Grant/Contract Number:
- P30 CA047904
- Resource Type:
- Accepted Manuscript
- Journal Name:
- EBioMedicine
- Additional Journal Information:
- Journal Volume: 71; Journal Issue: C; Journal ID: ISSN 2352-3964
- Publisher:
- Elsevier
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 60 APPLIED LIFE SCIENCES; theranostics; targeted radiotherapy; immunoPET; checkpoint immunotherapy; gliomas; bifunctional chelator
Citation Formats
Foster, Alexandra, Nigam, Shubhanchi, Tatum, David S., Raphael, Itay, Xu, Jide, Kumar, Rajeev, Plakseychuk, Elizabeth, Latoche, Joseph D., Vincze, Sarah, Li, Bo, Giri, Rajan, McCarl, Lauren H., Edinger, Robert, Ak, Murat, Peddagangireddy, Vishal, Foley, Lesley M., Hitchens, T. Kevin, Colen, Rivka R., Pollack, Ian F., Panigrahy, Ashok, Magda, Darren, Anderson, Carolyn J., Edwards, W. Barry, and Kohanbash, Gary. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. United States: N. p., 2021.
Web. doi:10.1016/j.ebiom.2021.103571.
Foster, Alexandra, Nigam, Shubhanchi, Tatum, David S., Raphael, Itay, Xu, Jide, Kumar, Rajeev, Plakseychuk, Elizabeth, Latoche, Joseph D., Vincze, Sarah, Li, Bo, Giri, Rajan, McCarl, Lauren H., Edinger, Robert, Ak, Murat, Peddagangireddy, Vishal, Foley, Lesley M., Hitchens, T. Kevin, Colen, Rivka R., Pollack, Ian F., Panigrahy, Ashok, Magda, Darren, Anderson, Carolyn J., Edwards, W. Barry, & Kohanbash, Gary. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. United States. https://doi.org/10.1016/j.ebiom.2021.103571
Foster, Alexandra, Nigam, Shubhanchi, Tatum, David S., Raphael, Itay, Xu, Jide, Kumar, Rajeev, Plakseychuk, Elizabeth, Latoche, Joseph D., Vincze, Sarah, Li, Bo, Giri, Rajan, McCarl, Lauren H., Edinger, Robert, Ak, Murat, Peddagangireddy, Vishal, Foley, Lesley M., Hitchens, T. Kevin, Colen, Rivka R., Pollack, Ian F., Panigrahy, Ashok, Magda, Darren, Anderson, Carolyn J., Edwards, W. Barry, and Kohanbash, Gary. Mon .
"Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma". United States. https://doi.org/10.1016/j.ebiom.2021.103571. https://www.osti.gov/servlets/purl/1904053.
@article{osti_1904053,
title = {Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma},
author = {Foster, Alexandra and Nigam, Shubhanchi and Tatum, David S. and Raphael, Itay and Xu, Jide and Kumar, Rajeev and Plakseychuk, Elizabeth and Latoche, Joseph D. and Vincze, Sarah and Li, Bo and Giri, Rajan and McCarl, Lauren H. and Edinger, Robert and Ak, Murat and Peddagangireddy, Vishal and Foley, Lesley M. and Hitchens, T. Kevin and Colen, Rivka R. and Pollack, Ian F. and Panigrahy, Ashok and Magda, Darren and Anderson, Carolyn J. and Edwards, W. Barry and Kohanbash, Gary},
abstractNote = {Background: Malignant gliomas are deadly tumours with few therapeutic options. Although immunotherapy may be a promising therapeutic strategy for treating gliomas, a significant barrier is the CD11b+ tumour-associated myeloid cells (TAMCs), a heterogeneous glioma infiltrate comprising up to 40% of a glioma's cellular mass that inhibits anti-tumour T-cell function and promotes tumour progression. A theranostic approach uses a single molecule for targeted radiopharmaceutical therapy (TRT) and diagnostic imaging; however, there are few reports of theranostics targeting the tumour microenvironment. Methods: Utilizing a newly developed bifunctional chelator, Lumi804, an anti-CD11b antibody (αCD11b) was readily labelled with either Zr-89 or Lu-177, yielding functional radiolabelled conjugates for PET, SPECT, and TRT. Findings: 89Zr/177Lu-labeled Lumi804-αCD11b enabled non-invasive imaging of TAMCs in murine gliomas. Additionally, 177Lu-Lumi804-αCD11b treatment reduced TAMC populations in the spleen and tumour and improved the efficacy of checkpoint immunotherapy. Interpretation: 89Zr- and 177Lu-labeled Lumi804-αCD11b may be a promising theranostic pair for monitoring and reducing TAMCs in gliomas to improve immunotherapy responses.},
doi = {10.1016/j.ebiom.2021.103571},
journal = {EBioMedicine},
number = C,
volume = 71,
place = {United States},
year = {Mon Sep 13 00:00:00 EDT 2021},
month = {Mon Sep 13 00:00:00 EDT 2021}
}
Works referenced in this record:
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
journal, December 2018
- Tamura, Ryota; Tanaka, Toshihide; Ohara, Kentaro
- Cancer Science, Vol. 110, Issue 2
89 Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89 Zr Radiochemistry
journal, August 2017
- Heskamp, Sandra; Raavé, René; Boerman, Otto
- Bioconjugate Chemistry, Vol. 28, Issue 9
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy
journal, June 2006
- Szatmari, Tunde; Lumniczky, Katalin; Desaknai, Szilvia
- Cancer Science, Vol. 97, Issue 6
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
journal, January 2020
- Enríquez Pérez, Julio; Kopecky, Jan; Visse, Edward
- BMC Cancer, Vol. 20, Issue 1
Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges
journal, May 2009
- Nayak, Tapan K.; Brechbiel, Martin W.
- Bioconjugate Chemistry, Vol. 20, Issue 5
Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
journal, October 2018
- Graham, Kaitlin; Unger, Evan
- International Journal of Nanomedicine, Vol. Volume 13
Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma
journal, February 2019
- Won, Woong-Jai; Deshane, Jessy S.; Leavenworth, Jianmei W.
- Cell Stress, Vol. 3, Issue 2
Theranostics in nuclear medicine practice
journal, January 2017
- Yordanova, Anna; Eppard, Elisabeth; Kürpig, Stefan
- OncoTargets and Therapy, Vol. Volume 10
Tumor infiltrating immune cells in gliomas and meningiomas
journal, March 2016
- Domingues, Patrícia; González-Tablas, María; Otero, Álvaro
- Brain, Behavior, and Immunity, Vol. 53
Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
journal, January 2019
- Chen, Haojun; Zhao, Liang; Fu, Kaili
- Theranostics, Vol. 9, Issue 25
3D Slicer as an image computing platform for the Quantitative Imaging Network
journal, November 2012
- Fedorov, Andriy; Beichel, Reinhard; Kalpathy-Cramer, Jayashree
- Magnetic Resonance Imaging, Vol. 30, Issue 9
Tumor-associated macrophages: an accomplice in solid tumor progression
journal, October 2019
- Chen, Yibing; Song, Yucen; Du, Wei
- Journal of Biomedical Science, Vol. 26, Issue 1
Reversed phase free ion selective radiotracer extraction (RP-FISRE): A new tool to assess the dynamic stabilities of metal (-organic) complexes, for complex half-lives spanning six orders of magnitude
journal, December 2013
- van der Meer, Astrid; Breeman, Wouter A. P.; Wolterbeek, Bert
- Applied Radiation and Isotopes, Vol. 82
177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
journal, April 2020
- Malenge, Marion M.; Patzke, Sebastian; Ree, Anne H.
- Journal of Nuclear Medicine, Vol. 61, Issue 10
Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis
journal, November 2018
- Dmochowska, Nicole; Tieu, William; Keller, Marianne D.
- Journal of Nuclear Medicine, Vol. 60, Issue 6
Intracranial glioma xenograft model rapidly reestablishes blood–brain barrier integrity for longitudinal imaging of tumor progression using fluorescence molecular tomography and contrast agents
journal, February 2020
- Habimana-Griffin, LeMoyne; Ye, Dezhuang; Carpenter, Julia
- Journal of Biomedical Optics, Vol. 25, Issue 02
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
journal, July 2015
- Perng, Powell; Lim, Michael
- Frontiers in Oncology, Vol. 5
Feasibility of 177Lu Therapy Monitoring Using Fast Whole-Body SPECT Recordings Provided by a High-Speed 360° CZT Camera
journal, June 2020
- Chevalier, Elodie; Boursier, Caroline; Claudin, Marine
- Clinical Nuclear Medicine, Vol. 45, Issue 11
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
journal, February 2005
- Kaminski, Mark S.; Tuck, Melissa; Estes, Judith
- New England Journal of Medicine, Vol. 352, Issue 5
Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
journal, June 2019
- Lamano, Jonathan B.; Lamano, Jason Balquidera; Li, Yuping D.
- Clinical Cancer Research, Vol. 25, Issue 12
Targeting tumor-associated myeloid cells for cancer immunotherapy
journal, March 2015
- Qin, Hong; Wei, Guowei; Gwak, Dongho
- OncoImmunology, Vol. 4, Issue 3
Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
journal, September 2013
- Tagawa, Scott T.; Milowsky, Matthew I.; Morris, Michael
- Clinical Cancer Research, Vol. 19, Issue 18
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
journal, March 2016
- Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii
- Trends in Immunology, Vol. 37, Issue 3
Mechanism and Energetics for Complexation of 90Y with 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA), a Model for Cancer Radioimmunotherapy
journal, June 1999
- Jang, Yun Hee; Blanco, Mario; Dasgupta, Siddharth
- Journal of the American Chemical Society, Vol. 121, Issue 26
The Synthesis and Chelation Chemistry of DOTA−Peptide Conjugates
journal, February 2008
- De León-Rodríguez, Luis M.; Kovacs, Zoltan
- Bioconjugate Chemistry, Vol. 19, Issue 2
Myeloid-derived cells are key targets of tumor immunotherapy
journal, April 2014
- Medina-Echeverz, José; Aranda, Fernando; Berraondo, Pedro
- OncoImmunology, Vol. 3, Issue 4
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
journal, September 2012
- Piao, Y.; Liang, J.; Holmes, L.
- Neuro-Oncology, Vol. 14, Issue 11
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides
journal, September 2008
- Liu, Shuang
- Advanced Drug Delivery Reviews, Vol. 60, Issue 12, p. 1347-1370
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
journal, January 2014
- van de Watering, Floor C. J.; Rijpkema, Mark; Perk, Lars
- BioMed Research International, Vol. 2014
Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer
journal, January 2020
- Niaz, Muhammad Junaid; Batra, Jaspreet S.; Walsh, Ryan D.
- The Oncologist, Vol. 25, Issue 6
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
journal, May 2021
- Raphael, Itay; Kumar, Rajeev; McCarl, Lauren H.
- Frontiers in Immunology, Vol. 12
Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy
journal, October 2017
- Porta, Chiara; Sica, Antonio; Riboldi, Elena
- The FEBS Journal, Vol. 285, Issue 4
Abraxane-induced bone marrow CD11b+ myeloid cell depletion in tumor-bearing mice is visualized by μPET-CT with 64Cu-labeled anti-CD11b and prevented by anti-CSF-1
journal, January 2021
- Cao, Qizhen; Huang, Qian; Wang, Y. Alan
- Theranostics, Vol. 11, Issue 7
PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody
journal, January 2021
- Ren, Jingyun; Xu, Mengxin; Chen, Junyi
- Theranostics, Vol. 11, Issue 1
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
journal, September 2013
- Pyonteck, Stephanie M.; Akkari, Leila; Schuhmacher, Alberto J.
- Nature Medicine, Vol. 19, Issue 10
PET Tracers Based on Zirconium-89
journal, April 2011
- Zhang, Yin; Hong, Hao; Cai, Weibo
- Current Radiopharmaceuticalse, Vol. 4, Issue 2
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
journal, January 2013
- Wesolowski, Robert; Markowitz, Joseph; Carson, William E.
- Journal for ImmunoTherapy of Cancer, Vol. 1, Issue 1
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
journal, July 2019
- Hennrich, Ute; Kopka, Klaus
- Pharmaceuticals, Vol. 12, Issue 3
Matching chelators to radiometals for radiopharmaceuticals
journal, January 2014
- Price, Eric W.; Orvig, Chris
- Chem. Soc. Rev., Vol. 43, Issue 1
Small-Animal PET/CT Imaging of Local and Systemic Immune Response Using 64Cu-αCD11b
journal, February 2019
- Cao, Qizhen; Huang, Qian; Mohan, Chandra
- Journal of Nuclear Medicine, Vol. 60, Issue 9
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
journal, October 2018
- Ostrom, Quinn T.; Gittleman, Haley; Truitt, Gabrielle
- Neuro-Oncology, Vol. 20, Issue suppl_4
Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology
journal, April 2003
- Cha, Soonmee; Johnson, Glyn; Wadghiri, Youssef Zaim
- Magnetic Resonance in Medicine, Vol. 49, Issue 5
Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs)
journal, September 2011
- Sica, Antonio; Porta, Chiara; Morlacchi, Sara
- Cancer Microenvironment, Vol. 5, Issue 2
The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery
journal, January 2013
- Russell, Jeffery S.; Brown, J. Martin
- Frontiers in Physiology, Vol. 4
PET imaging with 89Zr: From radiochemistry to the clinic
journal, January 2013
- Deri, Melissa A.; Zeglis, Brian M.; Francesconi, Lynn C.
- Nuclear Medicine and Biology, Vol. 40, Issue 1
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
journal, January 2019
- Hutter, Gregor; Theruvath, Johanna; Graef, Claus Moritz
- Proceedings of the National Academy of Sciences, Vol. 116, Issue 3
Theranostic Aspects: Treatment of Cancer by Nanotechnology
journal, June 2018
- Sarkar, Bidisha; Paira, Priyankar
- Mini-Reviews in Medicinal Chemistry, Vol. 18, Issue 11
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
journal, October 2019
- Arvanitis, Costas D.; Ferraro, Gino B.; Jain, Rakesh K.
- Nature Reviews Cancer, Vol. 20, Issue 1
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
journal, September 2018
- Kostelnik, Thomas I.; Orvig, Chris
- Chemical Reviews, Vol. 119, Issue 2
Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade
journal, September 2020
- Zhao, Xinrui; Shao, Chunlin
- Cancers, Vol. 12, Issue 10
Improved Efficacy of Synthesizing *M III -Labeled DOTA Complexes in Binary Mixtures of Water and Organic Solvents. A Combined Radio- and Physicochemical Study
journal, May 2018
- Pérez-Malo, Marylaine; Szabó, Gergely; Eppard, Elisabeth
- Inorganic Chemistry, Vol. 57, Issue 10
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
journal, March 2020
- Hennrich, Ute; Benešová, Martina
- Pharmaceuticals, Vol. 13, Issue 3
Tumor-Associated Microglia/Macrophages Enhance the Invasion of Glioma Stem-like Cells via TGF-β1 Signaling Pathway
journal, June 2012
- Ye, Xian-zong; Xu, Sen-lin; Xin, Yan-hong
- The Journal of Immunology, Vol. 189, Issue 1
Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy
journal, January 2017
- Kamran, Neha; Kadiyala, Padma; Saxena, Meghna
- Molecular Therapy, Vol. 25, Issue 1
Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
journal, May 2009
- Rockwell, Sara; Dobrucki, Iwona; Kim, Eugene
- Current Molecular Medicine, Vol. 9, Issue 4